Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2025 Earnings Convention Name Might 15, 2025 8:30 AM ET

Firm Individuals

Hayleigh Collins – Senior Director, Company Communications and Investor Relations
Sean P. Nolan – Chief Govt Officer
Sukumar Nagendran – President and Head of R&D
Kamran Alam – Chief Monetary Officer

Convention Name Individuals

Kristen Kluska – Cantor Fitzgerald
Gil Blum – Needham and Firm
Maury Raycroft – Jefferies
Yanan Zhu – Wells Fargo
Biren Amin – Piper Sandler
Whitney Ijem – Canaccord Genuity
Jack Allen – Baird
Joon Lee – Truist Securities
Silvan Tuerkcan – Residents
Malcolm Hoffman – BMO Capital Markets

Operator

Greetings, and welcome to the Taysha Gene Therapies First Quarter 2025 Earnings Name.

At the moment, all members are in a listen-only mode. An issue-and-answer session will comply with the formal presentation. [Operator Instructions] As a reminder, this convention is being recorded.

I’d now like to show the convention over to your host, Hayleigh Collins, Director, Head of Company Communications. Please go forward.

Hayleigh Collins

Thanks. Good morning, and welcome to Taysha’s first quarter 2025 monetary outcomes and company replace convention name.

Earlier immediately, Taysha issued a press launch asserting monetary outcomes for the primary quarter ended March 31, 2025. A replica of this press launch is on the market on the corporate’s web site and thru our SEC filings.

Becoming a member of me on immediately’s name are Sean Nolan, Taysha’s Chief Govt Officer; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Monetary Officer. We are going to maintain a question-and-answer session following our ready remarks.

Please notice that on immediately’s name, we might be making forward-looking statements, together with statements in regards to the potential of TSHA-102, together with the reproducibility and sturdiness of any favorable outcomes initially seen within the affected person’s dose to-date in medical trials to positively affect high quality of life and alter the course